v3.26.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities      
Net loss $ (11,667) $ (8,018) $ (4,240)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 12,781 11,888 10,253
Equity-based compensation 2,331 3,762 18,224
Non-cash interest expense; amortization of debt costs 525 339 207
Deferred income taxes (5,914) (252) 1,342
Loss on impairment of long-lived assets 4,575 16 (212)
Cost related to closing location 2,152 0 0
Changes in assets and liabilities      
Taxes receivable 1,556 (1,115) 890
Prepaid expense and other current assets (4,440) (2,059) 466
Other assets 6,669 (2,882) (4,711)
Accounts payable 579 739 (206)
Deferred revenue and patient deposits 735 (293) (896)
Accrued and other liabilities (6,786) 9,225 2,839
Net cash used in operating activities 3,096 11,350 23,956
Cash flows from investing activities      
Purchases of property and equipment, net (2,404) (14,007) (9,919)
Net cash used in investing activities (2,404) (14,007) (9,919)
Cash flows from financing activities      
Payments on term loan (13,793) (2,125) (12,125)
Payments for debt modification (393) (136) 0
Payments on revolving credit facility (5,000) 5,000 0
Proceeds from public offerings, net 18,764 0 0
Distribution to member 0 0 (79)
Dividends paid to shareholders 0 (252) (385)
Payment of taxes withheld through vested equity-based compensation (56) (903) (233)
Other financing activity 0 (954) (569)
Net cash used in financing activities (478) 630 (13,391)
Net decrease in cash and cash equivalents 214 (2,027) 646
Cash and cash equivalents      
Beginning of period 8,235 10,262 9,616
End of period 8,449 8,235 10,262
Supplemental disclosure of cash flow information:      
Cash paid for interest 5,562 5,997 6,277
Supplemental disclosure of non-cash investing information:      
Property and equipment included in accounts payable and accrued expenses $ 1,578 $ 1,595 $ 283